# The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

> **NCT04619680** · PHASE4 · COMPLETED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 103 (actual)

## Conditions studied

- Pulmonary Fibrosis
- Interstitial Lung Disease
- Respiratory Disease

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04619680
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-18
- **Primary completion:** 2024-02-01
- **Final completion:** 2024-03-02
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2026-04-30

## Collaborators

- Boehringer Ingelheim

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04619680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04619680, "The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04619680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*